Send to

Choose Destination
Expert Rev Pharmacoecon Outcomes Res. 2016 Oct;16(5):579-589. Epub 2016 Oct 6.

The impact of chronic conditions on the economic burden of cancer survivorship: a systematic review.

Author information

a Division of Cancer Prevention and Control , National Center for Chronic Disease Prevention and Health Promotion, CDC , Atlanta , GA , USA.
b U.S. Department of Health and Human Services , Office of Health Policy, Assistant Secretary for Planning and Evaluation , Washington , DC , USA.
c Health Sciences Library , University of North Carolina at Chapel Hill , Chapel Hill , NC , USA.


This systematic review examines the excess cost of chronic conditions on the economic burden of cancer survivorship among adults in the US. Areas covered: Twelve published studies were identified. Although studies varied substantially in populations, comorbidities examined, methods, and types of cost reported, costs for cancer survivors with comorbidities generally increased with greater numbers of comorbidities or an increase in comorbidity index score. Survivors with comorbidities incurred significantly more in total medical costs, out-of-pocket costs, and costs by service type compared to cancer survivors without additional comorbidities. Expert commentary: Cancer survivors with comorbidities bear significant excess out-of-pocket costs and their care is also more expensive to the healthcare system. On-going evaluation of different payment models, care coordination, and disease management programs for cancer survivors with comorbidities will be important in monitoring impact on healthcare costs.


Cancer survivors; chronic conditions; economic burden; systematic review

[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

Declaration of interest The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center